Effect of Losartan Treatment on Proteinuria and Urinary Transforming Growth Factor-beta1 in Human Chronic Glomerulonephritis.
- Author:
Hyeong Cheon PARK
1
;
Beom Seok KIM
;
Hoon Young CHOI
;
Shin Wook KANG
;
Kyu Hun CHOI
;
Sung Kyu HA
;
Ho Yung LEE
;
Dae Suk HAN
Author Information
1. Department of Internal Medicine, College of Medicine, Yonsei University, Seoul, Korea. dshan@yumc.yonsei.ac.kr
- Publication Type:Original Article
- Keywords:
Proteinuria;
Urinary TGF-beta1;
Losartan
- MeSH:
Angiotensins;
Blood Pressure;
Glomerulonephritis*;
Humans*;
Losartan*;
Prospective Studies;
Proteinuria*;
Renal Insufficiency, Chronic;
Transforming Growth Factor beta1
- From:Korean Journal of Nephrology
2004;23(2):231-240
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Urinary TGF-beta1 reflects intrarenal TGF-beta1 production and is increased in patients with progressive nephropathies. We studied the effects of angiotensin receptor blocker (ARB) on serum and urinary TGF-beta1 excretion in chronic glomerulonephritis patients with proteinuria. Also the role of urinary TGF-beta1 in ARB induced antiproteinuric responses was evaluated. METHODS: Patients with non-diabetic chronic renal disease with proteinuria of 1 g or more were enrolled in this open, prospective study. After four weeks of washout period, the patients received losartan 50 mg daily followed by 100 mg in two treatment periods each lasting 12 weeks. Clinical parameters and urinary indices including proteinuria and urinary TGF-beta1 were measured at baseline and after each 12 week treatment period. RESULTS: Among the 42 patients who completed the study, 31 responded to ARB therapy determined as a decrease in proteinuria by 30% (responders), and 11 did not respond (non-responders). ARB treatment controlled blood pressure to a similar degree in both responders and non-responders. Renal function and other biochemical parameters did not change during the study period. Both doses of losartan significantly lowered proteinuria and urinary TGF-beta1 excretion in responders (50 mg: 33.4% and 29.0%, 100 mg: 64.1% and 45.8%, respectively, p<0.05). In contrast, non-responders showed no significant reduction in proteinuria and no further decrease in urinary TGF-beta1 after 100 mg treatment. Urinary TGF-beta1 excretion lacked any correlation between clinical parameters such as proteinuria or renal function. Responders were younger, showed lower baseline proteinuria and urinary TGF-beta1 excretion and greater reduction in urinary TGF-beta1 excretion after ARB treatment. However, lower baseline urinary TGF-beta1 excretion was the only significant predictor of response to ARB therapy. CONCIUSION: Our data suggest that ARB therapy in nondiabetic proteinuric chronic glomerulonephritis patients reduces proteinuria and urinary TGF-beta1 excretion and baseline urinary TGF-beta1 excretion may predict antiproteinuric response to ARB therapy.
